Name | Value |
---|---|
Revenues | 24.0K |
Cost of Revenue | 368.0K |
Gross Profit | -344.0K |
Operating Expense | 8,909.0K |
Operating I/L | -9,253.0K |
Other Income/Expense | 950.0K |
Interest Income | 671.0K |
Pretax | -8,303.0K |
Income Tax Expense | -0.0K |
Net Income/Loss | -8,303.0K |
Sera Prognostics, Inc. is a women's health diagnostic company specializing in developing and commercializing biomarker tests to improve pregnancy outcomes. The company's flagship product, the PreTRM test, is a blood-based biomarker test designed to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. Additionally, Sera Prognostics is working on a range of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression.